Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Renal · FDA Approved

Vasopressin (ADH)

FDA-approved

How to ask your doctor
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A nine-amino acid cyclic peptide hormone (arginine vasopressin) produced in the hypothalamus and released from the posterior pituitary. Vasopressin acts on V1a receptors (vascular smooth muscle vasoconstriction), V1b receptors (ACTH release from the pituitary), and V2 receptors (water reabsorption in renal collecting ducts).

It is essential for body water homeostasis and blood pressure support.

02 · Research summary & key findings

Vasopressin injection was long sold as an older unapproved drug; after the FDA unapproved drugs initiative brought an approved product (Vasostrict, 2014) to market, hospital prices rose sharply (PMID 29944521). The approved product is indicated to raise blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. In the VASST trial, low-dose vasopressin added to catecholamines did not reduce 28-day mortality compared with norepinephrine in septic shock; mortality was lower in a prespecified less severe shock stratum, but the test for heterogeneity between strata was not significant (PMID 18305265).

03 · Regulatory status

Vasopressin (ADH) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Vasopressin (ADH) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

04 · Administration routes

  • Intravenous
  • Intramuscular injection
  • Subcutaneous injection

References

  1. [1]Vasopressin versus norepinephrine infusion in patients with septic shock N Engl J Med, 2008. PMID 18305265
  2. [2]US Food and Drug Administration Disruption of Generic Drug Market Increases Hospital Costs Anesth Analg, 2018. PMID 29944521

Primary literature

Related peptides in Renal

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.